Oral anticoagulant use in octogenarian European patients with atrial fibrillation: A subanalysis of PREFER in AF

International Journal of Cardiology

Volumn 232, Issue , 2017, Pages 98-104

  Hanon, Olivier ^a,b   Vidal, Jean Sébastien ^a,b   Le Heuzey, Jean Yves ^c   Kirchhof, Paulus ^d,e,f   De Caterina, Raffaele ^g,h   Schmitt, Josef ⁱ   Laeis, Petra ⁱ   Mannucci, Pier Mannuccio ^j,k   Marcucci, Maura ^j,k  

^a Paris Descartes University   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^f AFNET   (Germany)

^g UNIVERSITY OF CHIETI   (Italy)

^h Ospedale SS Annunziata   (Italy)

ⁱ DAIICHI SANKYO CO   (Japan)

^j FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^k UNIVERSITY OF MILAN   (Italy)

more..

Author keywords

Atrial fibrillation; Elderly: Oral anticoagulants: Multivariate analysis

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; CLOPIDOGREL; DABIGATRAN; DRONEDARONE; FLECAINIDE; FLUINDIONE; PHENPROCOUMON; PROPAFENONE; QUINIDINE; RIVAROXABAN; SOTALOL; WARFARIN;

AGE; AGED; ANTICOAGULANT THERAPY; ARTICLE; ARTIFICIAL HEART PACEMAKER; ATRIAL FIBRILLATION; BLEEDING; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DEFIBRILLATOR; DRUG USE; DYSPNEA; EUROPEAN; FATIGUE; FEMALE; HEART FAILURE; HEART PALPITATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; PAROXYSMAL ATRIAL FIBRILLATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; SELF CARE; CLINICAL TRIAL; COMPLICATION; CROSS-SECTIONAL STUDY; EUROPE; INCIDENCE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; REGISTER; RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; CROSS-SECTIONAL STUDIES; EUROPE; FEMALE; HUMANS; INCIDENCE; MALE; REGISTRIES; RISK FACTORS; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 85009830463     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2017.01.046     Document Type: Article

References (33)

1. [1] Nieuwlaat, R., Capucci, A., Camm, A.J., et al. Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on atrial fibrillation. Eur. Heart J. 26 (2005), 2422–2434.
2. [2] Nabauer, M., Gerth, A., Limbourg, T., et al. The registry of the German competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 11 (2009), 423–434.
3. [3] Ogilvie, I.M., Newton, N., Welner, S.A., Cowell, W., Lip, G.Y.H., Underuse of oral anticoagulants in atrial fibrillation: a systematic review. Am. J. Med. 123 (2010), 638–645.e4.
4. [4] Zimetbaum, P.J., Thosani, A., Yu, H., et al. Are atrial fibrillation patients receiving warfarin in accordance with stroke risk?. Am. J. Med. 123 (2010), 446–453.
5. [5] Go, A.S., Hylek, E.M., Borowsky, L.H., Phillips, K.A., Selby, J.V., Singer, D.E., Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann. Intern. Med. 131 (1999), 927–934.
6. [6] Lip, G.Y.H., Edwards, S.J., Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb. Res. 118 (2006), 321–333.
7. [7] Hanon, O., Vidal, J.S., Pisica-Donose, G., et al. Therapeutic management in ambulatory elderly patients with atrial fibrillation: the S.AGES cohort. J. Nutr. Health Aging 19 (2015), 219–227.
8. [8] Kirchhof, P., Ammentorp, B., Darius, H., et al. Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events–European Registry in Atrial Fibrillation (PREFER in AF). Europace 16 (2014), 6–14.
9. [9] Lip, G.Y.H., Nieuwlaat, R., Pisters, R., Lane, D.A., Crijns, H.J.G.M., Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137 (2010), 263–272.
10. [10] Camm, A.J., Kirchhof, P., Lip, G.Y.H., et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31 (2010), 2369–2429.
11. [11] Camm, A.J., Lip, G.Y.H., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur. Heart J. 33 (2012), 2719–2747.
12. [12] Heeringa, J., van der Kuip, D.A.M., Hofman, A., et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur. Heart J. 27 (2006), 949–953.
13. [13] Edholm, K., Ragle, N., Rondina, M.T., Antithrombotic management of atrial fibrillation in the elderly. Med. Clin. North Am. 99 (2015), 417–430.
14. [14] Wolf, P.A., D'Agostino, R.B., Belanger, A.J., Kannel, W.B., Probability of stroke: a risk profile from the Framingham Study. Stroke 22 (1991), 312–318.
15. [15] Barco, S., Cheung, Y.W., Eikelboom, J.W., Coppens, M., New oral anticoagulants in elderly patients. Best Pract. Res. Clin. Haematol. 26 (2013), 215–224.
16. [16] Poli, D., Antonucci, E., Testa, S., Tosetto, A., Ageno, W., Palareti, G., Bleeding risk in very old patients on vitamin K antagonist treatment: results of a prospective collaborative study on elderly patients followed by Italian centres for anticoagulation. Circulation 124 (2011), 824–829.
17. [17] Pradhan, A.A., Levine, M.A.H., Warfarin use in atrial fibrillation: a random sample survey of family physician beliefs and preferences. Can. J. Clin. Pharmacol. 9 (2002), 199–202.
18. [18] Mant, J., Hobbs, F.D.R., Fletcher, K., et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet 370 (2007), 493–503.
19. [19] Man-Son-Hing, M., Laupacis, A., Anticoagulant-related bleeding in older persons with atrial fibrillation: physicians' fears often unfounded. Arch. Intern. Med. 163 (2003), 1580–1586.
20. [20] Gattellari, M., Worthington, J.M., Zwar, N.A., Middleton, S., Barriers to using warfarin in non-valvular atrial fibrillation. BMJ 332 (2006), 303–304.
21. [21] Lip, G.Y.H., Laroche, C., Dan, G., et al. ‘Real-world’ antithrombotic treatment in atrial fibrillation: the EORP-AF pilot survey. Am. J. Med. 127 (2014), 519–529.e1.
22. [22] De Caterina, R., Ammentorp, B., Darius, H., et al. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. Heart 100 (2014), 1625–1635.
23. [23] Le Heuzey, J.Y., Ammentorp, B., Darius, H., et al. Differences among western European countries in anticoagulation management of atrial fibrillation. Data from the PREFER IN AF registry. Thromb. Haemost. 111 (2014), 833–841.
24. [24] Brooks, R., EuroQol: the current state of play. Health Policy 37 (1996), 53–72.
25. [25] Sankaranarayanan, R., Kirkwood, G., Dibb, K., Garratt, C.J., Comparison of atrial fibrillation in the young versus that in the elderly: a review. Cardiol. Res. Pract., 2013, 2013, 976976.
26. [26] Brunetti, N.D., De Gennaro, L., Pellegrino, P.L., Dellegrottaglie, G., Antonelli, G., Di Biase, M., Atrial fibrillation with symptoms other than palpitations: incremental diagnostic sensitivity with at-home tele-cardiology assessment for emergency medical service. Eur. J. Prev. Cardiol. 19 (2012), 306–313.
27. [27] Fitzmaurice, D.A., Hobbs, F.D.R., Jowett, S., et al. Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial. BMJ, 335, 2007, 383.
28. [28] Cohen, A., Dallongeville, J., Durand-Zaleski, I., Bouee, S., Le Heuzey, J.Y., Characteristics and management of outpatients with history of or current atrial fibrillation: the observational French EPHA study. Arch. Cardiovasc. Dis. 103 (2010), 376–387.
29. [29] Singer, D.E., Chang, Y., Fang, M.C., et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann. Intern. Med. 151 (2009), 297–305.
30. [30] Marcucci, M., Nobili, A., Tettamanti, M., et al. Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation. Eur. J. Intern. Med. 24 (2013), 800–806.
31. [31] Friberg, L., Hammar, N., Rosenqvist, M., Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. Eur. Heart J. 31 (2010), 967–975.
32. [32] Ruff, C.T., Giugliano, R.P., Braunwald, E., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 383 (2014), 955–962.
33. [33] Reilly, P.A., Lehr, T., Haertter, S., et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J. Am. Coll. Cardiol. 63 (2014), 321–328.